Literature DB >> 11133771

BCL-6 protein is expressed in precursor T-cell lymphoblastic lymphoma and in prenatal and postnatal thymus.

E Hyjek1, A Chadburn, Y F Liu, E Cesarman, D M Knowles.   

Abstract

The organization and expression of the BCL-6 gene in normal and neoplastic thymic T cells has not been fully determined. We examined 8 precursor T-cell lymphoblastic lymphomas (T-LBLs) and found significant BCL-6 expression in 4 cases. Three of the BCL-6(+) cases expressed a common thymocyte phenotype (CD4(+), CD8(+)), and one expressed a precursor thymocyte phenotype (CD4(-), CD8(-)). In 6 cases evaluated, including those expressing BCL-6, molecular analyses demonstrated a germline configuration of the BCL-6 gene and a wild-type BCL-6 gene first exon-intron boundary region. We also evaluated 12 normal prenatal and postnatal thymuses for BCL-6 protein. BCL-6 was expressed by most cortical thymocytes and by scattered medullary thymocytes. BCL-6(+) cortical and medullary thymocytes also expressed CD2, CD3, CD4, CD5, CD7, or CD8. We further analyzed the pattern of BCL-2 and BCL-X(L) expression and their coexpression with BCL-6 in normal thymus and T-LBL and compared it to that of follicle centers of reactive lymph nodes and follicular lymphoma. BCL-6(+) cortical thymocytes coexpressed BCL-X(L) but not BCL-2. All 4 BCL-6(+) T-LBLs and 4 BCL-6(-) T-LBLs coexpressed BCL-2 and BCL-X(L). Conceivably, T-LBLs may arise through clonal expansion of cortical thymocytes normally expressing the BCL-6 protein. The pattern of BCL-6, BCL-2, and BCL-X(L) expression in cortical thymocytes is highly reminiscent of germinal centers, and the abnormal coexpression of BCL-2, BCL-X(L), and BCL-6 in T-LBL is analogous to coexpression in follicle center cell lymphomas, suggesting that coexpression of these anti-apoptotic genes may contribute to the pathogenesis of T-LBL.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11133771     DOI: 10.1182/blood.v97.1.270

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  11 in total

1.  Peripheral T-cell lymphoma with involvement of the expanded mantle zone.

Authors:  Ida Münster Ikonomou; Anne Tierens; Gunhild Troen; Hege Vangstein Aamot; Sverre Heim; Grete F Lauritzsen; Helen Vålerhaugen; Jan Delabie
Journal:  Virchows Arch       Date:  2006-04-22       Impact factor: 4.064

2.  BCL6 BTB-specific inhibition via FX1 treatment reduces Tfh cells and reverses lymphoid follicle hyperplasia in Indian rhesus macaque (Macaca mulatta).

Authors:  Yanhui Cai; Meagan A Watkins; Fengtian Xue; Yong Ai; Huiming Cheng; Cecily C Midkiff; Xiaolei Wang; Xavier Alvarez; Adi Narayana Reddy Poli; Joseph M Salvino; Ronald S Veazey; Luis J Montaner
Journal:  J Med Primatol       Date:  2019-10-01       Impact factor: 0.667

3.  PIM1 gene cooperates with human BCL6 gene to promote the development of lymphomas.

Authors:  Beverly W Baron; John Anastasi; Elizabeth M Hyjek; Juraj Bies; Poluru L Reddy; Jingfang Dong; Loren Joseph; Michael J Thirman; Kristen Wroblewski; Linda Wolff; Joseph M Baron
Journal:  Proc Natl Acad Sci U S A       Date:  2012-03-26       Impact factor: 11.205

4.  Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010.

Authors:  Lawrence D Kaplan; Jeannette Y Lee; Richard F Ambinder; Joseph A Sparano; Ethel Cesarman; Amy Chadburn; Alexandra M Levine; David T Scadden
Journal:  Blood       Date:  2005-05-24       Impact factor: 22.113

5.  High levels of bcl-2 protein expression do not correlate with genetic abnormalities but predict worse prognosis in patients with lymphoblastic lymphoma.

Authors:  Yajun Gu; Yi Pan; Bin Meng; Bingxin Guan; Kai Fu; Baocun Sun; Fang Zheng
Journal:  Tumour Biol       Date:  2013-03-14

6.  The human BCL6 transgene promotes the development of lymphomas in the mouse.

Authors:  Beverly W Baron; John Anastasi; Anthony Montag; Dezheng Huo; Rebecca M Baron; Theodore Karrison; Michael J Thirman; Sumit K Subudhi; Robert K Chin; Dean W Felsher; Yang-Xin Fu; Timothy W McKeithan; Joseph M Baron
Journal:  Proc Natl Acad Sci U S A       Date:  2004-09-16       Impact factor: 11.205

7.  Characterization of childhood precursor T-lymphoblastic lymphoma by immunophenotyping and fluorescent in situ hybridization: a report from the Children's Oncology Group.

Authors:  Kristi J Smock; Marilu Nelson; Sheryl R Tripp; Warren G Sanger; Minnie Abromowitch; Mitchell S Cairo; Sherrie L Perkins
Journal:  Pediatr Blood Cancer       Date:  2008-10       Impact factor: 3.167

8.  Repression of the PDCD2 gene by BCL6 and the implications for the pathogenesis of human B and T cell lymphomas.

Authors:  Beverly W Baron; Nancy Zeleznik-Le; Miriam J Baron; Catherine Theisler; Dezheng Huo; Matthew D Krasowski; Michael J Thirman; Rebecca M Baron; Joseph M Baron
Journal:  Proc Natl Acad Sci U S A       Date:  2007-04-27       Impact factor: 11.205

9.  GFI1B, EVI5, MYB--additional genes that cooperate with the human BCL6 gene to promote the development of lymphomas.

Authors:  Beverly W Baron; John Anastasi; Juraj Bies; Poluru L Reddy; Loren Joseph; Michael J Thirman; Kristen Wroblewski; Linda Wolff; Joseph M Baron
Journal:  Blood Cells Mol Dis       Date:  2013-07-30       Impact factor: 3.039

10.  BTB-ZF factors recruit the E3 ligase cullin 3 to regulate lymphoid effector programs.

Authors:  Rebecca Mathew; Michael P Seiler; Seth T Scanlon; Ai-ping Mao; Michael G Constantinides; Clara Bertozzi-Villa; Jeffrey D Singer; Albert Bendelac
Journal:  Nature       Date:  2012-10-21       Impact factor: 49.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.